Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Tenofovir was associated with a lower risk of hepatocellular carcinoma, but this might be related to other factors as well.
Clinical trials often exclude key patient populations, including children and people living with HIV or hepatitis B or C.
People with HIV who have higher viral load and worse immune function appear to be at higher risk for hepatocellular carcinoma.
Researchers compared liver-related death rates among Mexicans, Puerto Ricans and Cubans.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
Cabometyx is the third liver cancer drug approved in the past six months.
Shawne Jabonero Lopes, DACM, LAc, shares her family’s liver health story.
A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Although the risk is low, periodic medical monitoring for liver cancer among those with hepatitis B surface antigen clearance is advised.
Benefits include lower rates of cancer recurrence and microvascular invasion, which is associated with poor post-surgery outcomes.
This includes a higher risk of liver cancer, cirrhosis-related complications and death.
Liver cancer rates and deaths have doubled in the United States, Canada, Australia and United Kingdom.
Liver cancer development is strongly associated with hep B.
Hepatitis B and C are declining as causes of liver cancer and liver transplants.
Those who smoke and have liver cancer but not viral hepatitis did not have such an elevated risk.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.